Douglas Wilson

Douglas Wilson

Company: Merck Research Laboratories

Job title: Principal Scientist

Seminars:

Development of MK-4830 (anti-ILT4 mAb) to Target Immunosuppressive Myeloid Cells for the Treatment of Human Malignancies 2:00 pm

MK-4830 is a fully human monoclonal antibody that targets ILT4 and blocks its binding to cognate ligands ILT4-blockade by MK-4830 alters the phenotype and function of myeloid-derived suppressor cells MK-4830 treatment induced tumor growth inhibition of a human cancer cell line in a humanized mouse model system MK-4830 and pembrolizumab combination therapy provides clinical benefit…Read more

day: Discovery & Pre-Clinical Development – Day 2 pm

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.